Christophe Ginestier

Summary

Country: France

Publications

  1. pmc p53 and cancer stem cells: The mevalonate connexion
    Christophe Ginestier
    Centre de Recherche en Cancérologie de Marseille Laboratoire d Oncologie Moléculaire UMR1068 Inserm Institut Paoli Calmettes Marseille, France
    Cell Cycle 11:2583-4. 2012
  2. pmc Targeting breast cancer stem cells: fishing season open!
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR Inserm Institut Paoli Calmettes, France
    Breast Cancer Res 12:312. 2010
  3. doi request reprint Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target
    Christophe Ginestier
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, INSERM, Institut Paoli Calmettes, 27 Boulevard Lei Roure, Marseille, France
    Stem Cells 30:1327-37. 2012
  4. pmc Retinoid signaling regulates breast cancer stem cell differentiation
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm Institut Paoli Calmettes, Marseilles, France
    Cell Cycle 8:3297-302. 2009
  5. pmc CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
    Christophe Ginestier
    University of Michigan Comprehensive Cancer Center, Department of Internal Medicine Oncology, Ann Arbor, Michigan 48109 0015, USA
    J Clin Invest 120:485-97. 2010
  6. pmc Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Cancer Res 69:1302-13. 2009
  7. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
  8. pmc Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer
    Emmanuelle Charafe-Jauffret
    Department of Molecular Oncology, Institut Paoli Calmettes UMR891 Institut National de la Sante et de la Recherche Medicale, Universite de la Mediterranee, Marseille Cancer Research Center, Marseille, France
    Clin Cancer Res 16:45-55. 2010
  9. ncbi request reprint Comparative multi-methodological measurement of ERBB2 status in breast cancer
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes et U119 INSERM, IFR57, Marseille, France
    J Pathol 202:286-98. 2004
  10. ncbi request reprint Moesin expression is a marker of basal breast carcinomas
    Emmanuelle Charafe-Jauffret
    Laboratory of Molecular Oncology, Marseille Cancer Research Institute, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    Int J Cancer 121:1779-85. 2007

Collaborators

Detail Information

Publications47

  1. pmc p53 and cancer stem cells: The mevalonate connexion
    Christophe Ginestier
    Centre de Recherche en Cancérologie de Marseille Laboratoire d Oncologie Moléculaire UMR1068 Inserm Institut Paoli Calmettes Marseille, France
    Cell Cycle 11:2583-4. 2012
    ..Comment on: Freed-Pastor WA, et al. Cell 2012; 148:244-58 and Ginestier C, et al. Stem Cells 2012; In press...
  2. pmc Targeting breast cancer stem cells: fishing season open!
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR Inserm Institut Paoli Calmettes, France
    Breast Cancer Res 12:312. 2010
    ..A large research effort is now aiming to develop drugs targeting CSCs, based either on a priori understanding of key pathways regulating CSC biology or on high-throughput screening to identify novel targets and compounds...
  3. doi request reprint Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target
    Christophe Ginestier
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, INSERM, Institut Paoli Calmettes, 27 Boulevard Lei Roure, Marseille, France
    Stem Cells 30:1327-37. 2012
    ..The identification of protein GG as a major contributor to CSC maintenance opens promising perspectives for CSC targeted therapy in basal breast cancer...
  4. pmc Retinoid signaling regulates breast cancer stem cell differentiation
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm Institut Paoli Calmettes, Marseilles, France
    Cell Cycle 8:3297-302. 2009
    ..These pathways regulate breast CSCs biology and their inhibition may provide novel therapeutic approaches to target breast CSCs...
  5. pmc CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
    Christophe Ginestier
    University of Michigan Comprehensive Cancer Center, Department of Internal Medicine Oncology, Ann Arbor, Michigan 48109 0015, USA
    J Clin Invest 120:485-97. 2010
    ..Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs...
  6. pmc Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Cancer Res 69:1302-13. 2009
    ....
  7. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  8. pmc Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer
    Emmanuelle Charafe-Jauffret
    Department of Molecular Oncology, Institut Paoli Calmettes UMR891 Institut National de la Sante et de la Recherche Medicale, Universite de la Mediterranee, Marseille Cancer Research Center, Marseille, France
    Clin Cancer Res 16:45-55. 2010
    ..To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this aggressive type of breast cancer...
  9. ncbi request reprint Comparative multi-methodological measurement of ERBB2 status in breast cancer
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes et U119 INSERM, IFR57, Marseille, France
    J Pathol 202:286-98. 2004
    ..A new combined IHC score based on the association of two selected anti-ERBB2 antibodies (HercepTest trade mark and TAB250) and a dual scale for improved assessment of ERBB2 protein expression, particularly in 2+ cases, are proposed...
  10. ncbi request reprint Moesin expression is a marker of basal breast carcinomas
    Emmanuelle Charafe-Jauffret
    Laboratory of Molecular Oncology, Marseille Cancer Research Institute, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    Int J Cancer 121:1779-85. 2007
    ..014). In multivariate analysis, Moesin expression was nearly an independent prognostic marker of poor outcome as shown by Cox proportional hazard model in patients without lymph node metastasis (p = 0.052, HR = 2.38, CI 95[0.99-5.69])...
  11. ncbi request reprint [Inflammatory breast carcinoma: towards molecular characterization?]
    Emmanuelle Charafe-Jauffret
    Département de biopathologie, Institut Paoli Calmettes, Marseille
    Ann Pathol 23:564-9. 2003
    ..It has been shown to be lost in IBC and could control tumor growth, invasion, and angiogenesis. This paper summarizes current knowledge on IBC and describes a new basis for a molecular definition of IBC...
  12. ncbi request reprint Prognosis and gene expression profiling of 20q13-amplified breast cancers
    Christophe Ginestier
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR599 Inserm, Marseilles, France
    Clin Cancer Res 12:4533-44. 2006
    ..Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized...
  13. ncbi request reprint Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Int J Cancer 107:854-62. 2003
    ..37 (1.21-4.64; p = 0.03). Thus, among the patients who present with tumors of apparent good prognosis, FHIT is an independent prognostic factor that distinguishes a subgroup of patients who could benefit from adjuvant treatment...
  14. ncbi request reprint ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program
    Emmanuelle Charafe-Jauffret
    Authors Affiliations INSERM, U1068, CRCM, Molecular Oncology, Institut Paoli Calmettes, Biopathology, Aix Marseille Univ, UM 105, F 13284, Départements d Oncologie Médicale, Chirugie oncologique, and Radiologie, Institut Paoli Calmettes, Marseille and Plateforme ARN interference PArI, CEA Saclay, Gif sur Yvette, France
    Cancer Res 73:7290-300. 2013
    ..Our work offers a proof of the functional importance of CSCs in breast cancer, and it establishes the reliability of PDXs for use in developing personalized CSC therapies for patients with breast cancer...
  15. ncbi request reprint A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene
    José Adélaïde
    Département d Oncologie Moléculaire, Laboratoires de Cytogénétique Moléculaire et de Pathologie Moléculaire, U119 Institut National de la Santé et de la Recherche Médicale INSERM and Institut Paoli Calmettes IPC, Marseille, France
    Genes Chromosomes Cancer 37:333-45. 2003
    ..PCR analysis of reverse-transcribed cell line RNAs revealed an extensive complexity of the NRG1 transcripts but failed to detect a consistent pattern of mRNA isoforms in the cell lines with NRG1 breakpoint...
  16. ncbi request reprint Identification and validation of an ERBB2 gene expression signature in breast cancers
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR119 Inserm, IFR57, and Faculté de Médecine, Universite de la Mediterranee, Marseille, France
    Oncogene 23:2564-75. 2004
    ..Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples...
  17. ncbi request reprint TACC1-chTOG-Aurora A protein complex in breast cancer
    Nathalie Conte
    Department of Molecular Oncology, U119 INSERM, Institut Paoli Calmettes, IFR57, Marseille, France
    Oncogene 22:8102-16. 2003
    ....
  18. pmc Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
    Anne Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:245. 2006
    ..Amplification status may provide diagnostic and prognostic information and may lead to new treatment strategies. Chromosomal regions 8p12, 8q24, 11q13, 17q12 and 20q13 are recurrently amplified in breast cancers...
  19. ncbi request reprint Protein expression profiling identifies subclasses of breast cancer and predicts prognosis
    Jocelyne Jacquemier
    Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR599 INSERM, 27 Boulevard Lei Roure, Marseille, France
    Cancer Res 65:767-79. 2005
    ..These results show that protein expression profiling may be a clinically useful approach to assess breast cancer heterogeneity and prognosis in stage I, II, or III disease...
  20. ncbi request reprint ETV6 gene rearrangements in invasive breast carcinoma
    Anne Letessier
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Institut Paoli Calmettes and UMR599 INSERM, Marseille, France
    Genes Chromosomes Cancer 44:103-8. 2005
    ..Of these samples, signal of sufficient quality for screening by FISH was obtained for 356. Five cases (one lobular, one nontypical secretory, one mixed, and two ductal carcinomas) showed ETV6 rearrangement...
  21. ncbi request reprint Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Institut Paoli Calmettes IPC, Marseille, France
    Int J Oncol 21:989-96. 2002
    ..In most samples, the TACC1 gene product was downregulated in tumor cells as compared to normal cells. Our results show that the centromeric portion of chromosome arm 8p is frequently altered in breast tumor cells...
  22. pmc Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling
    Hasan Korkaya
    Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    PLoS Biol 7:e1000121. 2009
    ....
  23. ncbi request reprint [Small but high throughput: how "tissue-microarrays" became a favorite tool for pathologists and scientists]
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, 232 Bd de Sainte Marguerite, 13273 Marseille Cedex 9, France
    Ann Pathol 23:623-32. 2003
    ..This Article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research...
  24. pmc Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and Institut National de la Santé et de la Recherche Medical U119, IFR57, Marseille, France
    Am J Pathol 161:1223-33. 2002
    ..Thus, differences extended to clinical prognostic information obtained by the two methods underlining their complementarity and the need for a global molecular analysis of tumors at both the RNA and protein levels...
  25. ncbi request reprint Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Institut Paoli Calmettes et U119 INSERM, IFR57, Marseille, France
    J Pathol 202:265-73. 2004
    ..0049 for OS and p < 0.0001 for DFS). In conclusion, an immunophenotypic signature was suggested for IBC. This could help to determine the worst cases, independent of clinical criteria...
  26. pmc BRCA1 regulates human mammary stem/progenitor cell fate
    Suling Liu
    Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 105:1680-5. 2008
    ..Because BRCA1 also plays a role in DNA repair, our work suggests that loss of BRCA1 may result in the accumulation of genetically unstable breast stem cells, providing prime targets for further carcinogenic events...
  27. ncbi request reprint Inflammatory breast cancers in Tunisia and France show similar immunophenotypes
    Emmanuelle Charafe-Jauffret
    Institut de Cancérologie de Marseille, Département d Oncologie Moléculaire, Institut Paoli Calmettes et UMR599 Inserm, IFR137 Marseille, France
    Breast 16:352-8. 2007
    ..It is thought that IBC occurs with a high frequency in Tunisia. The aim of this study is to evaluate this signature on a Tunisian series...
  28. pmc Targeting breast stem cells with the cancer preventive compounds curcumin and piperine
    Madhuri Kakarala
    Division of Hematology Oncology, Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, 2150 Cancer Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA
    Breast Cancer Res Treat 122:777-85. 2010
    ..Mammosphere formation assays may be a quantifiable biomarker to assess cancer preventive agent efficacy and Wnt signaling assessment can be a mechanistic biomarker for use in human clinical trials...
  29. pmc Nectin-4 is a new histological and serological tumor associated marker for breast cancer
    Stéphanie Fabre-Lafay
    INSERM, UMR599, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 7:73. 2007
    ..Nectins are cell adhesion molecules involved in the regulation of epithelial physiology. We present here Nectin-4/PVRL4 as a new histological and serological tumor associated marker for breast carcinoma...
  30. ncbi request reprint Typical medullary breast carcinomas have a basal/myoepithelial phenotype
    Jocelyne Jacquemier
    Marseille Cancer Institute, Molecular Oncology Department, UMR599 INSERM and Paoli Calmettes Institute, Marseille, France
    J Pathol 207:260-8. 2005
    ..In multivariate analysis with logistic regression, TMBC was defined by the association of P-cadherin (R=2.29), MIB1 > 50 (R=3.80), ERBB2 negativity (R=2.24) and p53 positivity (RR=1.45)...
  31. pmc MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells
    Suling Liu
    Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    PLoS Genet 8:e1002751. 2012
    ..These studies demonstrate that miRNAs can regulate the states and fates of normal and malignant mammary stem cells, findings which have important biological and clinical implications...
  32. pmc Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks
    Suling Liu
    Comprehensive Cancer Center and School of Dentistry, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 71:614-24. 2011
    ..Bone marrow-derived MSCs may accelerate human breast tumor growth by generating cytokine networks that regulate the CSC population...
  33. ncbi request reprint [Towards an integrated cellular and molecular: definition of breast cancers]
    Emmanuelle Charafe-Jauffret
    UMR 599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancérologie de Marseille et Université de la Méditerranée, 27, boulevard Lei Roure, 13009 Marseille, France
    Med Sci (Paris) 23:626-32. 2007
    ..These combined studies allow a new integrated cellular and molecular definition of breast cancers and a conceptual basis that will help the management of the disease...
  34. pmc Cancer stem cells in breast: current opinion and future challenges
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Pathobiology 75:75-84. 2008
    ..Following this approach, new molecules are currently in development. Focusing on the cross-talk between stem cells and their microenvironment is also a promising way to explore how to better target cancer stem cells and be curative...
  35. ncbi request reprint [The cancer stem cell: the breast cancer driver]
    Christophe Ginestier
    University of Michigan Medical Center, Comprehensive Cancer Center, Int Med Hematology Oncology, 1500 E Medical Center Drive, Ann Arbor, MI, USA
    Med Sci (Paris) 23:1133-9. 2007
    ..This model has fundamental implications for breast cancer treatment. The development of specific therapeutics that target this population is an important focus for the future...
  36. ncbi request reprint Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene
    Cornel Popovici
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, Marseille, France
    Genes Chromosomes Cancer 35:204-18. 2002
    ..Additional experiments using comparative genomic hybridization provided further information on the genomic context in which the t(3;20)(p14;p11) reciprocal translocation was found...
  37. pmc ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
    Fabrice Sircoulomb
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, INSERM, U891, Institut Paoli Calmettes, Marseille, France
    EMBO Mol Med 3:153-66. 2011
    ..Moreover, we show that ZNF703 is implicated in the regulation of ER and E2F1 transcription factor. These findings point out the prominent role of ZNF703 in transcription modulation, stem cell regulation and luminal B oncogenesis...
  38. doi request reprint Getting to the root of BRCA1-deficient breast cancer
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Marseille, France
    Cell Stem Cell 5:229-30. 2009
    ..In Nature Medicine, Lim et al. (2009) demonstrate that breast tissue from BRCA1 mutation carriers contains expanded luminal progenitor cells, suggesting a broader role for BRCA1 in mammary development...
  39. ncbi request reprint [Tissue microarrays a powerful tool in transfer and quality control in oncology]
    Jocelyne Jacquemier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, 232, Bd de Sainte Marguerite, 13273 Marseille Cedex 9
    Bull Cancer 90:31-8. 2003
    ..This article provides a short review of this technology, and points out several aspects of the TMA construction and its applications for clinical research...
  40. ncbi request reprint Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Oncogene 23:1377-91. 2004
    ..These results suggest that microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets...
  41. ncbi request reprint How to best classify breast cancer: conventional and novel classifications (review)
    Emmanuelle Charafe-Jauffret
    Marseille Cancer Institute, Laboratory of Molecular Oncology, UMR599 Inserm, Marseille, France
    Int J Oncol 27:1307-13. 2005
    ..We have tried here to confront the conventional existing classifications with this new molecular taxonomy. It is likely that using all types of classification together will help in the management of breast cancer...
  42. ncbi request reprint Basal and luminal breast cancers: basic or luminous? (review)
    Daniel Birnbaum
    Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and UMR599 INSERM, 13009 Marseille, France
    Int J Oncol 25:249-58. 2004
    ..The combined effects of these progresses on our understanding of breast cancer biology should have major consequences on the way this disease is managed...
  43. doi request reprint What drives breast cancer heterogeneity: oncogenic events or cell of origin?
    Christophe Ginestier
    Centre de Recherche en Cancérologie de Marseille CRCM, Laboratoire d Oncologie Moleculaire, Marseille, France
    J Pathol 227:267-9. 2012
    ..These and other recent observations underscore the importance of defining what is causing tumour heterogeneity, so that appropriate therapy can be given...
  44. pmc Breast cancer stem cells: tools and models to rely on
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 9:202. 2009
    ..In this review, we survey tools and markers available or promising to identify breast CSCs. We review the main models used to study breast CSCs and how they challenge the CSC hypothesis...
  45. pmc Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival
    Ines A Silva
    Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 71:3991-4001. 2011
    ..Taken together, our findings define ALDH and CD133 as a functionally significant set of markers to identify ovarian CSCs...
  46. ncbi request reprint Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators
    Nathalie Conte
    Département d Oncologie Moléculaire, U119 INSERM, 27 Bd Lei Roure, 13009, Marseille, France
    Oncogene 21:5619-30. 2002
    ..We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes...
  47. pmc Cancer stem cell vaccination confers significant antitumor immunity
    Ning Ning
    Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA
    Cancer Res 72:1853-64. 2012
    ..Together, these proof-of-concept results provide a rationale for a new type of cancer immunotherapy based on the development of CSC vaccines that can specifically target CSCs...